Calquence (acalabrutinib) Letter of Medical Necessity
Calquence (acalabrutinib) is a second-generation BTK inhibitor with improved cardiac safety over ibrutinib. PAs require diagnosis confirmation, cytogenetics, and line of therapy documentation.
FDA-Approved Indications
- ● chronic lymphocytic leukemia (CLL/SLL)
- ● mantle cell lymphoma
Why Calquence Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Diagnosis not confirmed by pathology/flow cytometry
- 2. Preferred BTK inhibitor (zanubrutinib) on formulary
- 3. FISH/cytogenetics not documented
- 4. Line of therapy not specified
What to Include in a Calquence Letter of Medical Necessity
Document CLL/SLL or MCL diagnosis with pathology confirmation, FISH/cytogenetics (del17p, TP53 mutation, IGHV status), prior therapies and outcomes, cardiac history, concurrent medications, and the rationale for acalabrutinib over other BTK inhibitors.
Key clinical evidence to cite:
- ✓ ELEVATE-TN (treatment-naïve CLL)
- ✓ ASCEND (relapsed/refractory CLL)
- ✓ ACE-LY-004 (MCL)
- ✓ ELEVATE-RR head-to-head vs ibrutinib
Relevant guidelines:
- 📖 NCCN CLL/SLL Guidelines
- 📖 NCCN B-cell Lymphomas Guidelines
Payers Covering Calquence
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Calquence Prior Authorization FAQ
Why was my Calquence prior authorization denied?
The most common denial reasons for Calquence are: Diagnosis not confirmed by pathology/flow cytometry; Preferred BTK inhibitor (zanubrutinib) on formulary; FISH/cytogenetics not documented; Line of therapy not specified.
What should a Calquence Letter of Medical Necessity include?
Document CLL/SLL or MCL diagnosis with pathology confirmation, FISH/cytogenetics (del17p, TP53 mutation, IGHV status), prior therapies and outcomes, cardiac history, concurrent medications, and the rationale for acalabrutinib over other BTK inhibitors.
Which payers cover Calquence?
Calquence is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part D, though formulary tier and prior authorization criteria vary.